Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
January 3, 2019

Flexion enrols first subject in Phase III trial of zilretta

Flexion Therapeutics has enrolled the first patient in a Phase III clinical trial to examine the safety and efficacy of zilretta (triamcinolone acetonide extended-release injectable suspension) for the treatment of patients with hip osteoarthritis (OA).

Flexion Therapeutics has enrolled the first patient in a Phase III clinical trial to examine the safety and efficacy of zilretta (triamcinolone acetonide extended-release injectable suspension) for the treatment of patients with hip osteoarthritis (OA).

Hip OA is a degenerative disease with no cure that is estimated to affect nearly a quarter of the US population in their lifetime.

Flexion aims to enrol 440 patients with hip OA pain as part of the double-blind, placebo-controlled trial.

Patients will be randomised in 1:1 ratio into one of two treatment groups to receive a single intra-articular (IA) injection of either zilretta or placebo.

After being treated with the first injection of zilretta or placebo, patients will be assessed at weeks 12, 16, 20 and 24 to determine the clinical requirement of a second IA injection.

“We believe zilretta may be able to play an important role in helping these patients find meaningful pain relief.”

Patients eligible for a second injection will be treated with open-label zilretta at the time of recurrent symptoms before being monitored for 12 weeks.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

The remaining patients who will not receive a second injection will be observed for up to 24 weeks after their first injection.

Primary objective of the trial is the scale of pain relief against placebo as assessed by the Western Ontario and McMaster Universities Osteoarthritis Index A (WOMAC A) subscale at week 12.

Flexion Therapeutics president and CEO Michael Clayman said: “Like OA of the knee, OA of the hip is a serious disease that can profoundly affect one’s quality of life.

“These impacts are compounded by the fact that there are so few non-surgical treatment options available to manage OA hip pain, and we believe zilretta may be able to play an important role in helping these patients find meaningful pain relief.

“We look forward to reporting the Phase III results with the expectation that the trial will read out in 2020.”

Flexion also intends to begin new Phase II studies of zilretta later this year.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU